In line with this, a clinical trial reported that the baseline serum from a child with severe OI displayed increased expression and activation of the TGF-β pathway, and that the TGF-β bioactivity was reduced after MSC therapy. Here, TGFB1 is linked to osteogenesis imperfecta.